Reducing Complications of Influenza: Update on the Use of Antiviral Agents in Vulnerable Patients

 
Release Date: October 28, 2019
Last Reviewed: October 21, 2019
Expiration Date: October 28, 2020
Time to Complete Activity: 1.0 hour
 
This activity is jointly provided by Educational Review Systems, Inc and Paradigm Medical Communications, LLC.  
                                                                                      
 
Faculty
Jason E. Bowling, MD, FIDSA
Associate Professor
Department of Medicine
Division of Infectious Diseases
UT Health San Antonio
San Antonio, TX
 
James S. Lewis II, PharmD, FIDSA
Infectious Diseases Pharmacy Supervisor
Co-Director, Antibiotic Stewardship
Departments of Pharmacy and Infectious Diseases
Oregon Health & Science University
Portland, OR
 
Target Audience
This activity has been designed to address the educational needs of community, health-system, and hospital pharmacists. It may also benefit other clinicians involved in the care of patients with, or at risk for, influenza virus infection.

Statement of Need
While influenza infection can be serious in any patient, those in high-risk groups are most susceptible to negative sequelae, including pneumonia, hospitalization, and death. Therefore, rapid identification and treatment of patients who are at high risk for influenza-related complications is strongly recommended by professional and government guidelines. This fast-paced, case-based activity will acquaint pharmacists with the latest updates on diagnostic testing and treatment (including the first novel antiviral therapy approved for the treatment of influenza in 20 years), so they are prepared to confidently counsel patients and colleagues on the best uses of these important strategies.
 
Learning Objectives
Upon proper completion of this activity, participants should be better able to:
  • Identify appropriate candidates for antiviral therapy based on risk for influenza-related complications, in accordance with current guideline recommendations
  • Determine the need for influenza treatment based on patient signs, symptoms, and accurate interpretation of appropriate diagnostic tests when necessary
  • Evaluate the latest safety and efficacy data for novel antiviral treatment to determine its role in the influenza treatment paradigm
 
Table of Contents
  • Introduction
  • Case Studies: Identifying Candidates for Antiviral Therapy
  • Antiviral Therapy for Influenza Treatment
Accreditation and Designation Statement
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.0 hours (0.10 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. (Universal Activity Number – 0761-9999-19-029-H01-P, 0761-9999-19-029-H01-T)

This is a knowledge-based activity.
 
Disclosure of Commercial Support
This activity is supported by an educational grant from Genentech, Inc.
 
Instructions for Participation
To receive CPE credit, you should:
  • Follow instructions to register or log in with your professional information and complete the
    pre-activity assessment
  • View the online activity in its entirety
  • Complete and submit the online posttest and evaluation
A statement of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.

Please note: To claim CPE credit, please make sure you include your date of birth and NABP number. All credit information will be uploaded into CPE Monitor within 30 days.
 
For questions regarding CPE credit, contact the Paradigm CME Department at (845) 398-5949.

There is no fee required for participation in this activity.

Hardware/Software Requirements
This certified CPE activity is designed using HTML5 video and audio. As you navigate the video using the supplied controls, the slides will sync to the speaker.
 
Supported Browsers:
For desktops (Windows/Mac)
Internet Explorer 9 or higher, Firefox 28 or higher, Safari 5.1 or higher, Google Chrome 31 or higher, Opera 21 or higher
 
For Tablets (iPad/Android/Surface)
iOS Safari 4 or higher, Android 2.3 or higher, IE Mobile 10 or higher
 
Technical Support: If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.
 
Disclosures
In accordance with ACPE requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
 
Faculty
Jason E. Bowling, MD
No financial relationships to disclose.
 
James S. Lewis II, PharmD, FIDSA
Retained Consultant: Merck & Co., Inc; Tetraphase Pharmaceuticals
 
Paradigm Medical Communications, LLC, staff members have no financial relationships to disclose.
 
Educational Review Systems, Inc., staff members have no financial relationships to disclose.

Resolution of Conflict of Interest
Educational Review Systems, Inc. and Paradigm Medical Communications, LLC have implemented a system to resolve conflicts of interest for each CPE activity to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public. Conflicts, if any, are resolved through one or more processes. All CPE content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACPE guidelines.
 
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.
 
Disclaimer
This CPE activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Educational Review Systems, Inc. or Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
 
If included, signed statements of informed consent granting permission for use have been obtained for all photographs and videos in which an individual can be identified.
 
As accredited providers, Educational Review Systems, Inc. and Paradigm Medical Communications, LLC must include a balanced view of therapeutic options in all activities. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Educational Review Systems, Inc. or Paradigm Medical Communications, LLC.
 
Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. Any views or opinions presented are solely those of the faculty, and do not necessarily represent those of Educational Review Systems, Inc., or Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Educational Review Systems, Inc., or Paradigm Medical Communications, LLC. Educational Review Systems, Inc., and Paradigm Medical Communications, LLC, accept no liability for the content referenced in this activity.
 
Privacy policy
Educational Review Systems, Inc., and Paradigm Medical Communications, LLC, are committed to protecting the privacy of those who participate in the activities (herein referred to as “website") located at www.paradigmmc.com. The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
 
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
 
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CPE activity. All evaluative information submitted is collected and retained, and used by Educational Review Systems, Inc., and Paradigm Medical Communications, LLC, to continuously improve the learning experience.
 
Educational Review Systems, Inc., and Paradigm Medical Communications, LLC, do not transfer, sell, or share personal information with outside parties. Educational Review Systems, Inc., and Paradigm Medical Communications, LLC, will not otherwise disclose personal information unless required to in a legal process. Educational Review Systems, Inc., and Paradigm Medical Communications, LLC, staff members review individual test results to the extent necessary to record and track participants’ credits.
 
Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.
 
© 2019 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.